Progress of ixazomib in treatment of multiple myeloma / 白血病·淋巴瘤
Journal of Leukemia & Lymphoma
;
(12): 505-508, 2020.
Article
in Chinese
| WPRIM
| ID: wpr-862868
ABSTRACT
Multiple myeloma (MM) is a clonal proliferation of abnormal plasma cells. Beginning with the use of proteasome inhibitor (PI), the treatment of MM has been significantly improved. Ixazomib is a new generation of PI, the clinical studies have shown that it has good efficacy and safety in frontline therapy, maintenance therapy and treatment of relapsed/refractory MM patients, mainly reflected in prolonging progression-free survival, low peripheral neurotoxicity and long-term medication without accumulated toxicity. This article reviews the mechanism of action, pharmacokinetics, clinical studies and adverse reactions of ixazomib, in order to provide references for the treatment of MM.
Full text:
Available
Index:
WPRIM (Western Pacific)
Language:
Chinese
Journal:
Journal of Leukemia & Lymphoma
Year:
2020
Type:
Article
Similar
MEDLINE
...
LILACS
LIS